Clinical Trial Update: Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of canakinumab for neonatal-onset multisystem inflammatory disease (NOMID/CINCA) was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cinca Syndrome
• Neonatal-onset Multisystem Inflammatory Disease
• Neonatal-onset Multisystem Inflammatory Disease with Nomid

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: NOMID, CINCA Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2021-06-10